Gastrointestinal Cancer

Recent strides in systemic treatment approaches and the broader application of stereotactic radiation led the American Society for Radiation Oncology to issue its first guideline regarding radiation therapy in patients with pancreatic cancer.

Timil Patel, MD, discusses an optimal sequencing strategy in rectal cancer.

The FDA has granted a priority review to a new drug application for pemigatinib as a treatment for patients with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements.

Lakshmi N. Rajdev, MD, discusses the use of somatostatin analogs in patients with neuroendocrine tumors.

The frontline combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) reduced the risk of disease progression or death by 42% compared with sorafenib (Nexavar) in patients with unresectable hepatocellular carcinoma.

Andreas Kaubisch, MD, discusses the phase III REACH and REACH-2 trials in advanced hepatocellular carcinoma.

Allyson Ocean, MD, discusses the use of circulating tumor DNA in pancreatic cancer.

Manish A. Shah, MD, discusses biomarkers in gastric and gastroesophageal junction cancer.

In a phase III trial, investigators are examining if arfolitixorin can supplant leucovorin calcium, a widely used component of combination regimens in patients with metastatic colorectal cancer.

Richard Kim, MD, discusses treatment options for BRAF-mutant colon cancer.

Manuel Hidalgo Medina, MD, PhD, discusses the emergence of neoadjuvant chemotherapy and radiation in pancreatic cancer.

Nonalcoholic fatty liver disease, a risk factor linked to the development of hepatocellular carcinoma and increased mortality, is growing in clinical significance.

Allyson Ocean, MD, discusses efforts to improve early detection rates in pancreatic cancer.

Cathy Eng, MD, FACP, FASCO, discusses unique barriers facing patients with early-onset colorectal cancer.

Varlitinib combined with capecitabine did not improve progression-free survival nor overall response rate compared with capecitabine/placebo as a second-line treatment in patients with biliary tract cancer.

The FDA has granted a priority review designation to a supplemental biologics license application for the combination of nivolumab and ipilimumab for the treatment of patients with advanced hepatocellular carcinoma who received prior therapy with sorafenib.

Andreas Kaubisch, MD, sheds light on systemic therapies available in liver cancer and some of the practice-changing phase III trials that have read out in the space.

Avelumab did not improve overall survival as frontline maintenance following induction chemotherapy in patients with unresectable, locally advanced, or metastatic HER2-negative gastric or gastroesophageal junction cancer.

Allyson Ocean, MD, discusses pivotal trials in early pancreatic cancer, the need for genetic testing, and other research efforts focused on improving patient outcomes.

Lakshmi N. Rajdev, MD, an associate professor, Department of Medicine (Oncology), at Albert Einstein College of Medicine, Montefiore Medical Center, discusses the difference between cancers and carcinomas in neuroendocrine tumors (NETs).

Ryan B. Corcoran, MD, PhD, discusses emerging therapeutics for patients with relapsed/refractory colorectal cancer.

The investigational agent pegvorhyaluronidase alfa in combination with gemcitabine and nab-paclitaxel did not show an improvement in overall survival compared with gemcitabine and nab-paclitaxel alone in patients with metastatic pancreatic cancer, missing the primary endpoint of the phase III HALO-109-301 trial.